Unknown

Dataset Information

0

Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma.


ABSTRACT: Dabrafenib is an inhibitor of BRAF V600E used for treating metastatic melanoma but a majority of patients experience adverse effects. Methods to measure the levels of dabrafenib and major metabolites during treatment are needed to allow development of individualized dosing strategies to reduce the burden of such adverse events. In this study, an LC-MS/MS method capable of measuring dabrafenib quantitatively and six metabolites semi-quantitatively is presented. The method is fully validated with regard to dabrafenib in human plasma in the range 5-5000 ng/mL. The analytes were separated on a C18 column after protein precipitation and detected in positive electrospray ionization mode using a Xevo TQ triple quadrupole mass spectrometer. As no commercial reference standards are available, the calibration curve of dabrafenib was used for semi-quantification of dabrafenib metabolites. Compared to earlier methods the presented method represents a simpler and more cost-effective approach suitable for clinical studies. Graphical abstract Combined multi reaction monitoring transitions of dabrafenib and metabolites in a typical case sample.

SUBMITTER: Vikingsson S 

PROVIDER: S-EPMC5427163 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma.

Vikingsson Svante S   Dahlberg Jan-Olof JO   Hansson Johan J   Höiom Veronica V   Gréen Henrik H  

Analytical and bioanalytical chemistry 20170420 15


Dabrafenib is an inhibitor of BRAF V600E used for treating metastatic melanoma but a majority of patients experience adverse effects. Methods to measure the levels of dabrafenib and major metabolites during treatment are needed to allow development of individualized dosing strategies to reduce the burden of such adverse events. In this study, an LC-MS/MS method capable of measuring dabrafenib quantitatively and six metabolites semi-quantitatively is presented. The method is fully validated with  ...[more]

Similar Datasets

| S-EPMC4332660 | biostudies-literature
| S-EPMC3879626 | biostudies-literature
| S-EPMC3963402 | biostudies-literature
| S-EPMC7204625 | biostudies-literature
| S-EPMC6874373 | biostudies-literature
| S-EPMC4390350 | biostudies-literature
| S-EPMC4966666 | biostudies-literature
| S-EPMC7788027 | biostudies-literature
| S-EPMC4034390 | biostudies-literature
| S-EPMC10071349 | biostudies-literature